header_image_2x new
Webinar 1 wit
Webinar 2 groen
Webinar 3 blauw


Latest insights on bacterial contamination in platelet concentrates

Wednesday January 27th | 3:00 – 4:15 pm (Central European Time)


time_2x3:00 – 3:10 pm

Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus Europe

time_2x3:10 – 3:35 pm

Bacterial contamination rate of platelet components by primary culture and residual risk associated with false negatives: results from two recent meta-analyses 
Ryan A. Metcalf | Medical Director, Blood Bank Assistant Professor; Inpatient Chief Value Officer; Department of Pathology | University of Utah and ARUP Laboratories

Multiple individual studies have reported bacterial contamination rates for both whole blood and apheresis platelet collections. Based on a systematic review of published data and meta-analysis best estimates of bacterial contamination rates were obtained for apheresis, platelet rich plasma and buffy coat collection methods. The impact of collection method, sample volume, positivity criteria, and study date on the bacterial contamination rate was determined. A second systematic review and meta-analysis evaluated risk associated with false negative primary culture results. 

time_2x3:35 - 4:00 pm

Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported?
Richard Benjamin | Chief Medical Officer | Cerus Global Headquarters

Contaminated platelets are often transfused, yet septic reactions are reported infrequently.
contaminated platelets that do not cause sepsis clinically relevant? Why do septic transfusion reactions often go unnoticed? What are the reasons that only a minority of suspected reactions reported by hospitals are confirmed and are reported in official hemovigilance reports?

time_2x4:00 – 4:15 pm

Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus

Please make your choice

I would like to register for webinar 3


I cannot register for webinar 3, but would like to receive access to the recorded webinar

New call-to-action



Global headquarters

1220 Concord Avenue
Concord, CA US 94520
+1 925.288.6000

European headquarters

Stationsstraat 79-D
3811 MH Amersfoort, Netherlands
+31 (0)33 49 60 600


Copyright 2021, CERUS. All rights reserved. MKT-EN 00477-14, v3.0

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. Follow us on LinkedIn.